Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation

Overview

Journal Inflamm Bowel Dis

Publisher Oxford University Press

Specialty Gastroenterology

Date 2017 Dec 23

PMID 29272494

Citations 4

Authors

Michael Laffin

Troy Perry

Heekuk Park

Naomi Hotte

Richard N Fedorak

Aducio Thiesen

Bryan Dicken

Karen L Madsen

Affiliations

Soon will be listed here.

Abstract

Background: Individuals with Crohn's disease frequently require ileocecal resection (ICR), and inflammation often recurs in the neoterminal ileum following surgery. Fructooligosaccharide (FOS) is a fermentable prebiotic that stimulates the growth of bifidobacteria and may promote anti-inflammatory activity. The aim of this study was to determine if supplementation of a postICR diet with FOS in a mouse model would be effective in stimulating the growth of bifidobacteria and reducing systemic and local inflammation.

Methods: ICR was performed in IL10-/- mice (129S1/SvlmJ) with colitis. Following surgery, nonICR control and ICR mice were fed a chow diet ± 10% FOS for 28 days. Serum, colon, and terminal ileum (TI) were analyzed for cytokine expression by MesoScale discovery platform. DNA extracted from stool was analyzed using 16s rRNA sequencing and qPCR. Expression of occludin and ZO1 was assessed using qPCR. Short-chain fatty acid (SCFA) concentrations were assessed using gas chromatography.

Results: ICR led to increased systemic inflammation (P < 0.05) and a significant decline in fecal microbial diversity (P < 0.05). Mice on the FOS diet had a greater reduction in microbial diversity and also had worsened inflammation as evidenced by increased serum IL-6 (P < 0.05) and colonic IFNγ and TNFα (P < 0.05). Expression of occludin and ZO1 were significantly reduced in FOS-supplemented mice. There was a correlation between loss of diversity and the bifidogenic effectiveness of FOS (r = -0.61, P < 0.05).

Conclusions: FOS-supplementation of a postICR diet resulted in a decrease in fecal bacterial diversity, reduction in barrier function, and increased gut inflammation.

Citing Articles

Recipient microbiome-related features predicting metabolic improvement following fecal microbiota transplantation in adults with severe obesity and metabolic syndrome: a secondary analysis of a phase 2 clinical trial.

Zhang Z, Mocanu V, Deehan E, Hotte N, Zhu Y, Wei S Gut Microbes. 2024; 16(1):2345134.

PMID: 38685731 PMC: 11062372. DOI: 10.1080/19490976.2024.2345134.

Changes in HLA-B27 Transgenic Rat Fecal Microbiota Following Tofacitinib Treatment and Ileocecal Resection Surgery: Implications for Crohn's Disease Management.

Blondeaux A, Valibouze C, Speca S, Rousseaux C, Dubuquoy C, Blanquart H Int J Mol Sci. 2024; 25(4).

PMID: 38396840 PMC: 10889215. DOI: 10.3390/ijms25042164.

What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?.

van Dorst J, Tam R, Ooi C Nutrients. 2022; 14(3).

PMID: 35276841 PMC: 8840103. DOI: 10.3390/nu14030480.

Timing of Tributyrin Supplementation Differentially Modulates Gastrointestinal Inflammation and Gut Microbial Recolonization Following Murine Ileocecal Resection.

Mocanu V, Park H, Dang J, Hotte N, Thiesen A, Laffin M Nutrients. 2021; 13(6).

PMID: 34204288 PMC: 8233937. DOI: 10.3390/nu13062069.

References

Riedel C, Foata F, Philippe D, Adolfsson O, Eikmanns B, Blum S . Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol. 2006; 12(23):3729-35. PMC: 4087466. DOI: 10.3748/wjg.v12.i23.3729. View

Ley R, Lozupone C, Hamady M, Knight R, Gordon J . Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 2008; 6(10):776-88. PMC: 2664199. DOI: 10.1038/nrmicro1978. View

Peyrin-Biroulet L, Loftus Jr E, Colombel J, Sandborn W . The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2009; 105(2):289-97. DOI: 10.1038/ajg.2009.579. View

Onali S, Calabrese E, Petruzziello C, Lolli E, Ascolani M, Ruffa A . Post-operative recurrence of Crohn's disease: A prospective study at 5 years. Dig Liver Dis. 2016; 48(5):489-494. DOI: 10.1016/j.dld.2016.01.009. View

Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C . Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001; 121(3):580-91. DOI: 10.1053/gast.2001.27224. View

Rios-Covian D, Gueimonde M, Duncan S, Flint H, de Los Reyes-Gavilan C . Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol Lett. 2015; 362(21). DOI: 10.1093/femsle/fnv176. View

Winkler J, Butler R, Symonds E . Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis. Dig Dis Sci. 2006; 52(1):52-8. DOI: 10.1007/s10620-006-9224-z. View

Kaplan H, Hutkins R . Fermentation of fructooligosaccharides by lactic acid bacteria and bifidobacteria. Appl Environ Microbiol. 2000; 66(6):2682-4. PMC: 110601. DOI: 10.1128/AEM.66.6.2682-2684.2000. View

Borowiec A, Sydora B, Doyle J, Guan L, Churchill T, Madsen K . Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. J Surg Res. 2012; 178(1):147-54. DOI: 10.1016/j.jss.2012.01.048. View

10.

Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K . Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011; 469(7331):543-7. DOI: 10.1038/nature09646. View

11.

Ten Bruggencate S, Bovee-Oudenhoven I, Lettink-Wissink M, van der Meer R . Dietary fructooligosaccharides increase intestinal permeability in rats. J Nutr. 2005; 135(4):837-42. DOI: 10.1093/jn/135.4.837. View

12.

Perry T, Borowiec A, Dicken B, Fedorak R, Madsen K . Murine ileocolic bowel resection with primary anastomosis. J Vis Exp. 2014; (92):e52106. PMC: 4353383. DOI: 10.3791/52106. View

13.

Xia J, Sinelnikov I, Han B, Wishart D . MetaboAnalyst 3.0--making metabolomics more meaningful. Nucleic Acids Res. 2015; 43(W1):W251-7. PMC: 4489235. DOI: 10.1093/nar/gkv380. View

14.

Fedorak R, Feagan B, Hotte N, Leddin D, Dieleman L, Petrunia D . The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol. 2014; 13(5):928-35.e2. DOI: 10.1016/j.cgh.2014.10.031. View

15.

Koleva P, Valcheva R, Sun X, Ganzle M, Dieleman L . Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr. 2012; 108(9):1633-43. DOI: 10.1017/S0007114511007203. View

16.

Lopez P, Gueimonde M, Margolles A, Suarez A . Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010; 138(1-2):157-65. DOI: 10.1016/j.ijfoodmicro.2009.12.023. View

17.

De Vuyst L, Leroy F . Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifdobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol. 2011; 149(1):73-80. DOI: 10.1016/j.ijfoodmicro.2011.03.003. View

18.

Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L . Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2005; 55(2):205-11. PMC: 1856500. DOI: 10.1136/gut.2005.073817. View

19.

Heuvelin E, Lebreton C, Grangette C, Pot B, Cerf-Bensussan N, Heyman M . Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors. PLoS One. 2009; 4(4):e5184. PMC: 2667252. DOI: 10.1371/journal.pone.0005184. View

20.

Rutgeerts P . Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol. 2003; 17(1):63-73. DOI: 10.1053/bega.2002.0358. View